Neurodegeneration with brain iron accumulation

Handbook of Clinical Neurology

Volumn 145, Issue , 2018, Pages 157-166

  Wiethoff, Sarah ^a,b   Houlden, Henry ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

dystonia; genetics; movement disorders; NBIA; neurodegeneration with brain iron accumulation; neuropathology; pallidopyramidal disorders

Indexed keywords

IRON; PANTOTHENATE KINASE; PHOSPHOTRANSFERASE;

BRAIN; GENETICS; HUMAN; IRON METABOLISM DISORDER; METABOLISM; MUTATION; NEUROAXONAL DYSTROPHY; PATHOLOGY;

BRAIN; HUMANS; IRON; IRON METABOLISM DISORDERS; MUTATION; NEUROAXONAL DYSTROPHIES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 85037081102     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-12-802395-2.00011-0     Document Type: Chapter

References (104)

1. Aggarwal, A., Schneider, S.A., Houlden, H., et al. Indian-subcontinent NBIA: unusual phenotypes, novel PANK2 mutations, and undetermined genetic forms. Mov Disord 25 (2010), 1424–1431.
2. Aicardi, J., Castelein, P., Infantile neuroaxonal dystrophy. Brain 102 (1979), 727–748.
3. Alazami, A.M., Al-Saif, A., Al-Semari, A., et al. Mutations in C2orf37, encoding a nucleolar protein, cause hypogonadism, alopecia, diabetes mellitus, mental retardation, and extrapyramidal syndrome. Am J Hum Genet 83 (2008), 684–691.
4. Al-Semari, A., Bohlega, S., Autosomal-recessive syndrome with alopecia, hypogonadism, progressive extra-pyramidal disorder, white matter disease, sensory neural deafness, diabetes mellitus, and low IGF1. Am J Med Genet A 143 (2007), 149–160.
5. Balsinde, J., Balboa, M.A., Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell Signal 17 (2005), 1052–1062.
6. Behrens, M.I., Bruggemann, N., Chana, P., et al. Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. Mov Disord 25 (2010), 1929–1937.
7. Bras, J., Verloes, A., Schneider, S.A., et al. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet 21 (2012), 2646–2650.
8. Castelnau, P., Cif, L., Valente, E.M., et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann Neurol 57 (2005), 738–741.
9. Chang, C.L., Lin, C.M., Eye-of-the-tiger sign is not pathognomonic of pantothenate kinase-associated neurodegeneration in adult cases. Brain Behav 1 (2011), 55–56.
10. Chinnery, P.F., Crompton, D.E., Birchall, D., et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 130 (2007), 110–119.
11. Cossu, G., Abbruzzese, G., Matta, G., et al. Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up. Parkinsonism Relat Disord 20 (2014), 651–654.
12. Curtis, A.R., Fey, C., Morris, C.M., et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 28 (2001), 350–354.
13. Defendini, R., Markesbery, W.R., Mastri, A.R., et al. Hallervorden-Spatz disease and infantile neuroaxonal dystrophy. Ultrastructural observations, anatomical pathology and nosology. J Neurol Sci 20 (1973), 7–23.
14. Delgado, R.F., Sanchez, P.R., Speckter, H., et al. Missense PANK2 mutation without “eye of the tiger” sign: MR findings in a large group of patients with pantothenate kinase-associated neurodegeneration (PKAN). J Magn Reson Imaging 35 (2012), 788–794.
15. Di Fonzo, A., Chien, H.F., Socal, M., et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68 (2007), 1557–1562.
16. Dick, K.J., Eckhardt, M., Paisan-Ruiz, C., et al. Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum Mutat 31 (2010), E1251–E1260.
17. Dusi, S., Valletta, L., Haack, T.B., et al. Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am J Hum Genet 94 (2014), 11–22.
18. Ebrahimi-Fakhari, D., Saffari, A., Wahlster, L., et al. Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism. Brain 139 (2016), 317–337.
19. Edvardson, S., Hama, H., Shaag, A., et al. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am J Hum Genet 83 (2008), 643–648.
20. Egan, R.A., Weleber, R.G., Hogarth, P., et al. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome). Am J Ophthalmol 140 (2005), 267–274.
21. Eidelberg, D., Sotrel, A., Joachim, C., et al. Adult onset Hallervorden-Spatz disease with neurofibrillary pathology. A discrete clinicopathological entity. Brain 110 (1987), 993–1013.
22. Garone, C., Pippucci, T., Cordelli, D.M., et al. FA2H-related disorders: a novel c.270 + 3A > T splice-site mutation leads to a complex neurodegenerative phenotype. Dev Med Child Neurol 53 (2011), 958–961.
23. Gonzalez-Cuyar, L.F., Perry, G., Miyajima, H., et al. Redox active iron accumulation in aceruloplasminemia. Neuropathology 28 (2008), 466–471.
24. Gregory, A., Hayflick, S., Neurodegeneration with brain iron accumulation disorders overview. Pagon, R.A., Adam, M.P., Ardinger, H.H., et al. (eds.), 1993, GeneReviews(R), Seattle (WA).
25. Gregory, A., Hayflick, S.J., Genetics of neurodegeneration with brain iron accumulation. Curr Neurol Neurosci Rep 11 (2011), 254–261.
26. Gregory, A., Kurian, M.A., Maher, E.R., et al. PLA2G6-Associated Neurodegeneration. Pagon, R.A., Adam, M.P., Ardinger, H.H., et al. (eds.), 1993, GeneReviews(R), Seattle (WA).
27. Gregory, A., Westaway, S.K., Holm, I.E., et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 71 (2008), 1402–1409.
28. Gregory, A., Polster, B.J., Hayflick, S.J., Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 46 (2009), 73–80.
29. Grunewald, A., Arns, B., Seibler, P., et al. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiol Aging 33:1843 (2012), e1841–e1847.
30. Gusdon, A.M., Zhu, J., Van Houten, B., et al. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. Neurobiol Dis 45 (2012), 962–972.
31. Haack, T.B., Hogarth, P., Kruer, M.C., et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet 91 (2012), 1144–1149.
32. Haraguchi, T., Terada, S., Ishizu, H., et al. Coexistence of TDP-43 and tau pathology in neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome). Neuropathology 31 (2011), 531–539.
33. Hartig, M.B., Iuso, A., Haack, T., et al. Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet 89 (2011), 543–550.
34. Hartmann, H.A., White, S.K., Levine, R.L., Neuroaxonal dystrophy with neuromelanin deposition, neurofibrillary tangles, and neuronal loss. Light- and electron-microscopic changes in a 45-year-old woman with progressive psychomotor deterioration. Acta Neuropathol 61 (1983), 169–172.
35. Hautot, D., Pankhurst, Q.A., Morris, C.M., et al. Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients. Biochim Biophys Acta 1772 (2007), 21–25.
36. Hayflick, S.J., Neurodegeneration with brain iron accumulation: from genes to pathogenesis. Semin Pediatr Neurol 13 (2006), 182–185.
37. Hayflick, S.J., Westaway, S.K., Levinson, B., et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 348 (2003), 33–40.
38. Hayflick, S.J., Hartman, M., Coryell, J., et al. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 27 (2006), 1230–1233.
39. Hayflick, S.J., Kruer, M.C., Gregory, A., et al. Beta-propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain 136 (2013), 1708–1717.
40. Hogarth, P., Neurodegeneration with brain iron accumulation: diagnosis and management. J Mov Disord 8 (2015), 1–13.
41. Hogarth, P., Gregory, A., Kruer, M.C., et al. New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 80 (2013), 268–275.
42. Hortnagel, K., Prokisch, H., Meitinger, T., An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria. Hum Mol Genet 12 (2003), 321–327.
43. Horvath, R., Lewis-Smith, D., Douroudis, K., et al. SCP2 mutations and neurodegeneration with brain iron accumulation. Neurology 85 (2015), 1909–1911.
44. Illingworth, M.A., Meyer, E., Chong, W.K., et al. PLA2G6-associated neurodegeneration (PLAN): Further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease. Mol Genet Metab, 2014.
45. Jaberi, E., Rohani, M., Shahidi, G.A., et al. Identification of mutation in GTPBP2 in patients of a family with neurodegeneration accompanied by iron deposition in the brain. Neurobiol Aging, 2015.
46. Keogh, M.J., Jonas, P., Coulthard, A., et al. Neuroferritinopathy: a new inborn error of iron metabolism. Neurogenetics 13 (2012), 93–96.
47. Khateeb, S., Flusser, H., Ofir, R., et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am J Hum Genet 79 (2006), 942–948.
48. Kono, S., Miyajima, H., Molecular and pathological basis of aceruloplasminemia. Biol Res 39 (2006), 15–23.
49. Koshy, G., Danda, S., Thomas, N., et al. Three siblings with Woodhouse-Sakati syndrome in an Indian family. Clin Dysmorphol 17 (2008), 57–60.
50. Kotzbauer, P.T., Truax, A.C., Trojanowski, J.Q., et al. Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci 25 (2005), 689–698.
51. Kruer, M.C., Boddaert, N., Neurodegeneration with brain iron accumulation: a diagnostic algorithm. Semin Pediatr Neurol 19 (2012), 67–74.
52. Kruer, M.C., Gregory, A., Hayflick, S.J., Fatty acid hydroxylase-associated neurodegeneration. Pagon, R.A., Adam, M.P., Ardinger, H.H., et al. (eds.) GeneReviews(R), 1993, University of Washington, Seattle, WA.
53. Kruer, M.C., Paisan-Ruiz, C., Boddaert, N., et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 68 (2010), 611–618.
54. Kruer, M.C., Hiken, M., Gregory, A., et al. Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 134 (2011), 947–958.
55. Kruer, M.C., Boddaert, N., Schneider, S.A., et al. Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am J Neuroradiol 33 (2012), 407–414.
56. Kurian, M.A., Morgan, N.V., MacPherson, L., et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 70 (2008), 1623–1629.
57. Kurian, M.A., McNeill, A., Lin, J.P., et al. Childhood disorders of neurodegeneration with brain iron accumulation (NBIA). Dev Med Child Neurol 53 (2011), 394–404.
58. Larsson, P.K., Claesson, H.E., Kennedy, B.P., Multiple splice variants of the human calcium-independent phospholipase A2 and their effect on enzyme activity. J Biol Chem 273 (1998), 207–214.
59. Li, A., Paudel, R., Johnson, R., et al. Pantothenate kinase-associated neurodegeneration is not a synucleinopathy. Neuropathol Appl Neurobiol 39 (2013), 121–131.
60. Liao, X., Luo, Y., Zhan, Z., et al. SPG35 contributes to the second common subtype of AR-HSP in China: frequency analysis and functional characterization of FA2H gene mutations. Clin Genet, 2014, 10.1111/cge.12336.
61. Machner, B., Sprenger, A., Behrens, M.I., et al. Eye movement disorders in ATP13A2 mutation carriers (PARK9). Mov Disord 25 (2010), 2687–2689.
62. Maciel, P., Cruz, V.T., Constante, M., et al. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology 65 (2005), 603–605.
63. Malik, I., Turk, J., Mancuso, D.J., et al. Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am J Pathol 172 (2008), 406–416.
64. Mancuso, M., Davidzon, G., Kurlan, R.M., et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol 64 (2005), 280–294.
65. Marelli, C., Piacentini, S., Garavaglia, B., et al. Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegeneration. Mov Disord 20 (2005), 208–212.
66. McNeill, A., Birchall, D., Hayflick, S.J., et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 70 (2008), 1614–1619.
67. McNeill, A., Pandolfo, M., Kuhn, J., et al. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 60 (2008), 200–205.
68. Mikati, M.A., Yehya, A., Darwish, H., et al. Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration. Eur J Paediatr Neurol 13 (2009), 61–64.
69. Miyajima, H., Aceruloplasminemia, an iron metabolic disorder. Neuropathology 23 (2003), 345–350.
70. Morgan, N.V., Westaway, S.K., Morton, J.E., et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 38 (2006), 752–754.
71. Najim al-Din, A.S., Wriekat, A., Mubaidin, A., et al. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 89 (1994), 347–352.
72. Nardocci, N., Zorzi, G., Farina, L., et al. Infantile neuroaxonal dystrophy: clinical spectrum and diagnostic criteria. Neurology 52 (1999), 1472–1478.
73. Ogimoto, M., Anzai, K., Takenoshita, H., et al. Criteria for early identification of aceruloplasminemia. Intern Med 50 (2011), 1415–1418.
74. Oide, T., Yoshida, K., Kaneko, K., et al. Iron overload and antioxidative role of perivascular astrocytes in aceruloplasminemia. Neuropathol Appl Neurobiol 32 (2006), 170–176.
75. Paisan-Ruiz, C., Bhatia, K.P., Li, A., et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 65 (2009), 19–23.
76. Paisan-Ruiz, C., Li, A., Schneider, S.A., et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 33 (2012), 814–823.
77. Park, J.S., Mehta, P., Cooper, A.A., et al. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum Mutat 32 (2011), 956–964.
78. Paudel, R., Li, A., Wiethoff, S., et al. Neuropathology of Beta-propeller protein associated neurodegeneration (BPAN): a new tauopathy. Acta Neuropathol Commun, 3, 2015, 39.
79. Perez, R., Melero, R., Balboa, M.A., et al. Role of group VIA calcium-independent phospholipase A2 in arachidonic acid release, phospholipid fatty acid incorporation, and apoptosis in U937 cells responding to hydrogen peroxide. J Biol Chem 279 (2004), 40385–40391.
80. Pierson, T.M., Simeonov, D.R., Sincan, M., et al. Exome sequencing and SNP analysis detect novel compound heterozygosity in fatty acid hydroxylase-associated neurodegeneration. Eur J Hum Genet 20 (2012), 476–479.
81. Ramirez, A., Heimbach, A., Grundemann, J., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38 (2006), 1184–1191.
82. Saitsu, H., Nishimura, T., Muramatsu, K., et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat Genet, 45(445–449), 2013, 449e441.
83. Savoiardo, M., Halliday, W.C., Nardocci, N., et al. Hallervorden-Spatz disease: MR and pathologic findings. AJNR Am J Neuroradiol 14 (1993), 155–162.
84. Schneider, S.A., Bhatia, K.P., Three faces of the same gene: FA2H links neurodegeneration with brain iron accumulation, leukodystrophies, and hereditary spastic paraplegias. Ann Neurol 68 (2010), 575–577.
85. Schneider, S.A., Bhatia, K.P., Syndromes of neurodegeneration with brain iron accumulation. Semin Pediatr Neurol 19 (2012), 57–66.
86. Schneider, S.A., Aggarwal, A., Bhatt, M., et al. Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology 67 (2006), 940–943.
87. Schneider, S.A., Paisan-Ruiz, C., Quinn, N.P., et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 25 (2010), 979–984.
88. Schule, R., Schols, L., Genetics of hereditary spastic paraplegias. Semin Neurol 31 (2011), 484–493.
89. Shinzawa, K., Sumi, H., Ikawa, M., et al. Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. J Neurosci 28 (2008), 2212–2220.
90. Stamelou, M., Lai, S.C., Aggarwal, A., et al. Dystonic opisthotonus: a “red flag” for neurodegeneration with brain iron accumulation syndromes?. Mov Disord 28 (2013), 1325–1329.
91. Stevanin, G., Azzedine, H., Denora, P., et al. Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain 131 (2008), 772–784.
92. Strecker, K., Hesse, S., Wegner, F., et al. Eye of the tiger sign in multiple system atrophy. Eur J Neurol 14 (2007), e1–e2.
93. Strokin, M., Seburn, K.L., Cox, G.A., et al. Severe disturbance in the Ca2 + signaling in astrocytes from mouse models of human infantile neuroaxonal dystrophy with mutated Pla2g6. Hum Mol Genet 21 (2012), 2807–2814.
94. Timmermann, L., Pauls, K.A., Wieland, K., et al. Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain 133 (2010), 701–712.
95. van den Bogaard, S.J., Kruit, M.C., Dumas, E.M., et al. Eye-of-the-tiger-sign in a 48 year healthy adult. J Neurol Sci 336 (2014), 254–256.
96. Vidal, R., Ghetti, B., Takao, M., et al. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J Neuropathol Exp Neurol 63 (2004), 363–380.
97. Wakabayashi, K., Yoshimoto, M., Fukushima, T., et al. Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies. Neuropathol Appl Neurobiol 25 (1999), 363–368.
98. Williams, D.R., Hadeed, A., al-Din, A.S., et al. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 20 (2005), 1264–1271.
99. Wilson, G.R., Sim, J.C., McLean, C., et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with alpha-synuclein pathology. Am J Hum Genet 95 (2014), 729–735.
100. Woodhouse, N.J., Sakati, N.A., A syndrome of hypogonadism, alopecia, diabetes mellitus, mental retardation, deafness, and ECG abnormalities. J Med Genet 20 (1983), 216–219.
101. Yoshida, K., Kaneko, K., Miyajima, H., et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J Neurol Sci 175 (2000), 91–95.
102. Yoshino, H., Tomiyama, H., Tachibana, N., et al. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 75 (2010), 1356–1361.
103. Zhou, B., Westaway, S.K., Levinson, B., et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 28 (2001), 345–349.
104. Zorzi, G., Zibordi, F., Chiapparini, L., et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord 26 (2011), 1756–1759.